Evidence map›Paper›PMID 26576533›Full record

Trial reportTrials2015

The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial.

Michael D Jenkinson, Mohsen Javadpour, Brian J Haylock, Bridget Young, Helen Gillard, Jacqui Vinten, Helen Bulbeck, Kumar Das, Michael Farrell, Seamus Looby and 6 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 9 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 9 syntheses or guidelines pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Michael D JenkinsonDepartment of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. michael.jenkinson@liv.ac.uk.
Mohsen JavadpourDepartment of Neurosurgery, Beaumont Hospital, Dublin 9, Ireland. mjavadpour@me.com.
Brian J HaylockDepartment of Clinical Oncology, Clatterbridge Cancer Centre, Wirral, CH63 4JY, UK. brian.haylock@clatterbridgecc.nhs.uk.
Bridget YoungInstitute of Psychology Health and Society, University of Liverpool, Liverpool, L69 7BE, UK. byoung@liv.ac.uk.
Helen GillardNeuropsychology, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. hgillard@liv.ac.uk.
Jacqui VintenNeuropsychology, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. jacqui.vinten@thewaltoncentre.nhs.uk.
Helen BulbeckClinical Trials Research Centre, University of Liverpool, Liverpool, L69 7BE, UK. helen@brainstrust.org.uk.
Kumar DasNeuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK. kumar.das@thewaltoncentre.nhs.uk.
Michael FarrellNeuropathology, Beaumont Hospital, Dublin 9, Ireland. michaelfarrell@baeumont.ie.
Seamus LoobyNeuroradiology, Beaumont Hospital, Dublin 9, Ireland. seamuslooby@beaumont.ie.
Helen HickeyClinical Trials Research Centre, University of Liverpool, Liverpool, L69 7BE, UK. h.hickey@liv.ac.uk.
Mattheus PreusserDepartment of Medicine, Comprehensive Cancer Center Vienna, CNS Unit, Medical University of Vienna, A-1090, Vienna, Austria. matthias.preusser@meduniwien.ac.at.
Conor L MallucciInstitute of Translational Medicine, University of Liverpool, Liverpool, L69 7BE, UK. cmallucci@me.com.
Dyfrig HughesCentre for Health Economics and Medicines Evaluation, Bangor University, Bangor, LL57 1UT, UK. d.a.hughes@bangor.ac.uk.
Carrol GambleClinical Trials Research Centre, University of Liverpool, Liverpool, L69 7BE, UK. c.gamble@liv.ac.uk.
Damien C WeberCentre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland. damien.weber@psi.ch.
University of Liverpool · GBBeaumont Hospital · IEWalton Centre · GBBangor University · GBClatterbridge Cancer Centre NHS Foundation Trust · GBMedical University of Vienna · ATPaul Scherrer Institute · CH

Funding

Department of Health HTA/12/173/14
6 · The paper itself

Abstract

backgroundAtypical meningiomas are an intermediate grade brain tumour with a recurrence rate of 39-58 %. It is not known whether early adjuvant radiotherapy reduces the risk of tumour recurrence and whether the potential side-effects are justified. An alternative management strategy is to perform active monitoring with magnetic resonance imaging (MRI) and to treat at recurrence. There are no randomised controlled trials comparing these two approaches. METHODS/

designA total of 190 patients will be recruited from neurosurgical/neuro-oncology centres across the United Kingdom, Ireland and mainland Europe. Adult patients undergoing gross total resection of intracranial atypical meningioma are eligible. Patients with multiple meningioma, optic nerve sheath meningioma, previous intracranial tumour, previous cranial radiotherapy and neurofibromatosis will be excluded. Informed consent will be obtained from patients. This is a two-stage trial (both stages will run in parallel): Stage 1 (qualitative study) is designed to maximise patient and clinician acceptability, thereby optimising recruitment and retention. Patients wishing to continue will proceed to randomisation. Stage 2 (randomisation) patients will be randomised to receive either early adjuvant radiotherapy for 6 weeks (60 Gy in 30 fractions) or active monitoring. The primary outcome measure is time to MRI evidence of tumour recurrence (progression-free survival (PFS)). Secondary outcome measures include assessing the toxicity of the radiotherapy, the quality of life, neurocognitive function, time to second line treatment, time to death (overall survival (OS)) and incremental cost per quality-adjusted life year (QALY) gained. DISCUSSION: ROAM/EORTC-1308 is the first multi-centre randomised controlled trial designed to determine whether early adjuvant radiotherapy reduces the risk of tumour recurrence following complete surgical resection of atypical meningioma. The results of this study will be used to inform current neurosurgery and neuro-oncology practice worldwide.

trial registrationISRCTN71502099 on 19 May 2014.

Indexed as

Cranial IrradiationNeurosurgical ProceduresClinical ProtocolsCost-Benefit AnalysisDisease-Free SurvivalDisease ProgressionDose Fractionation, RadiationEuropeHealth Care CostsHumansMagnetic Resonance ImagingMeningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalPredictive Value of TestsQuality-Adjusted Life Years

Identifiers

PMID26576533
PMCPMC4650615
OpenAlexW2173591426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.